Cambridge Cognition Share Discussion Threads

[somerset lad] 24/2/2023 13:35

Cogstate received a bid approach in Dec 22, granted data room access in Jan 23 and discussions ceased on 18 Feb: hxxps://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02635798-3A613526?access_token=83ff96335c2d45a094df02a206a39ff4

[sspurt] 06/2/2023 14:36

Given the severe illiquidity of these shares, average daily vol <40k, I think it is positive that the board have picked up 53,500 shares between them. Not often decent chunks come loose so such opportunities for the board are no doubt limited.

[40 fathoms] 06/2/2023 07:37

It is penance for delaying profitability for at least 18 months with the Winterlight acquisition.

It is a bit shocking that Richard Bungay has been on the board for almost 3 years and had never bought a share before Friday. Does not reflect well on him.

[purplepelmets] 06/2/2023 07:26

What's with all the bods buyong 10,000 shrs? Looks as authentic as jordans waps. Some bonus or the like?

[40 fathoms] 04/2/2023 02:32

Link is to press release from Aardex group from earlier this week about an integration of their adherence product in to our Clinpal digital clinical trails platform. While not huge in itself it does demonstrate the network effect that Cambridge Cognition is starting to develop. They are becoming the digital pluming to digital CNS trials to which others will plug their niche solutions and products.

[earwacks] 03/2/2023 14:39

Thanks for that Sev. It is really just repeating the RNS . Good to bring it to their readers attention though. I think this is an exciting project. i have a brother in law who heads up a brain remapping science lab joint project between France and China so looking forward to catching up with him soon. Someone on stockopedia tried to suggest that it would be easy to replicate some aspects of COG, but naturally didnt produce any detail or evidence. The exciting part for me is that this is very much becoming a global collaboration and that in itself must give it some protection because it is quite a small world and a lot these guys and gals all know each other in this particular area. The business side and making it work financial is another challenge. Seems to me they are well equipped to make it work even if it takes a couple more years to really take off.

[sev22] 02/2/2023 20:22

Cambridge Cognition in the best of health:

[sev22] 02/2/2023 20:18

Cambridge Cognition in the best of health:

[40 fathoms] 01/2/2023 22:58

Here is a current job that they have on offer. I do wonder if they really need a "Market Intelligence Analyst" at this point in time.

In my view a nice to have like this should only be considered when you are comfortably profitable. Revenue growth is wonderful, but not if it does not lead to profit and EPS growth. I want to start hearing management talk about profitability, particularly when and how much. I want to know that we will not be doing any more acquisition that are not EPS positive and I want to know if the huge growth we have seen in payroll, is a permeant feature or just a one off enhancement of the corporate structure. It is time for management to start being explicit about these things.

[earwacks] 01/2/2023 16:52

35,000 sell at the bell. Not sure if thats 1 trade published twice because the time is identical. Think there will be buyers at this price another duly stepped up for 16k at the bell. I’ve not finished yet either

[cerrito] 01/2/2023 16:24

40 Fathoms you were right to highlight the fact that in September Dowgate were forecasting a breakeven PBT for 2023 and now they have a £1m LBT for 2023.I note there has been no change in Dowgate forecast of year end 2023 net cash of £4m.
Glad I resisted the urge to buy more yesterday and trading volumes today so far at least and yesterday not all that heavy.
Note also that they have not participated in the 22pc January rally in the Goldman Sacha non profitable techbasket

[earwacks] 01/2/2023 15:19

Interesting to see if this just back to the most recent trade range where it sparked my interest. Again it’s a case of very small trades exaggerating the share price fall because of the small size of the company. Am keen to buy more but will wait to see where it heads next and if it can bounce of this recent low of a few weeks back. Actually keenness got the better and have doubled up!

[40 fathoms] 01/2/2023 14:19

It seems like we will have to wait at least 18 months until we move sustainably in to profitability, I suspect that length of wait will be viewed by some us too long and they will see better near term alternatives for their money.

Thankfully there are no cash worries.

[earwacks] 31/1/2023 10:19

Can’t say I’m too surprised at market reaction. Partly the market is flat anyway and trade very thin, plus this is quite a racy valuation on current figures.however the acquisition of Winterlight looks like a pretty canny deal with part share valued @£1.16ish. Every confidence that the business is well managed and the building blocks for accelerated growth are being established. Will be watching and accumulating.

[mike24] 31/1/2023 08:26

uk covid cases spike 50% in last 10 days
with new Kraken sub-variant, such an increase means its very contagious
125,000 cases last sat alone

[sev22] 31/1/2023 07:57

Cambridge Cognition says FY revenues will be ahead of market expectations:

[40 fathoms] 31/1/2023 07:27

Trading update is out. All looks positive. Revenue was ahead of market expectations at GBP 12.6 million. 11.7 million was low estimate (Dowgate) and 12 million was high (PG).

Profit for the year is @ 200k in line with consensus expectations.

Backlog including recent acquisitions is in excess of GBP 20 million. Of this @9.5 million is due to be recognised in 2023. They say this gives @60% 60% visibility on market forecast revenues for 2023. Which would suggest we are expecting to do @ 16 million in revenue. Before the TU Dowgate were @GBP 14.7 million and PG were @GBP 15.9 million. Both are forecasting losses for 2023 of between GBP 1 million and GBP 1.6 million.

[40 fathoms] 30/1/2023 23:33

As far as the share price is concerned I think it will be a pretty important update. Operationally, we know it will be in line and we can expect the overall outlook for the business to remain strong, however I feel some shareholders will be disappointed if management do not provide a clear roadmap for the next 2 or 3 years that demonstrates good levels of sustained and growing profitability.

[cerrito] 30/1/2023 18:27

Remember that the company anticipates issuing a TS this week

[greyingsurfer] 18/1/2023 08:00

The RNS in fact states :"An event changing the breakdown of voting rights",I.e related to the change in total share count, from the Winterlight acquisition.

[40 fathoms] 17/1/2023 23:08

I don't think you can concluded from the TR1 that he has sold stock. To pay for the Winterlight acquisition new shares were issued on Monday. This has increased the number of shares in issue which has had the effect of diluting existing holders. Even if he had not sold any shares, he would have still slipped below the 3% threshold and would have needed to report a change. You will note that Pendall also made a similar declaration today.

[earwacks] 17/1/2023 18:36

Looks like Stephen Perring has been selling the stock down. Hope this RNS means he is now out.

[40 fathoms] 14/1/2023 01:33

More success from Monument Therapeutics. A little bit surprised that this did not warrant an RNS.



It looks like they have been able to get their generic API across the blood-brain barrier in humans. This is a huge step. As a reminder this is a reformulated generic drug so the safety profile is well understood.

There is no currently no approved neuro anti-inflammatory and one would have many, many applications from TBI to stroke through to dementia and beyond. You will recall that we have a double digit topline royalty over Monument's pipeline as well as an equity position. This is worth keeping an eye on, as for less than GBP65k of book value Cambridge Cognition has 2 programs that (given the generic nature of the reformulated drugs) are highly likely to enter phase II. The commercial revenue potential of both programs individually would be in excess of US$ 1 billion of annual sales. Success in either of the programs would be worth 100's of millions to us. At the current market cap this is a free carry to Cambridge shareholders.

[cerrito] 13/1/2023 18:00

A propos today's change of holdings RNS, I see there were only 2 during 2022-both in relation to the reduction by Michael Buxton. A remarkably stable shareholder bass for a company in COG's stage of corporate development.